
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences is expected to experience significant growth in the near future, driven by the potential approval and launch of its smoking cessation drug, cytisinicline, in the United States in 2027. The company has completed a successful end-of-Phase 2 meeting with the FDA and has a well-defined regulatory path toward approval. Additionally, the company is also working on a potential treatment for vaping cessation, with a high probability of success and reduced risk due to the potential approval of cytisinicline. The upside potential of the stock at its current levels is favorable, with a 60% chance of success and potential partnerships in the future. However, potential risks such as commercial execution, clinical trials, regulatory approvals, and financing still remain a concern.
Bears say
Achieve Life Sciences is facing uncertainty and potential challenges in their FDA review process due to their prior reliance on a third-party manufacturer, which they have since transitioned away from. While today's announcement of no new clinical deficiencies is a positive update, the CRL still affects their timeline for resubmission. Additionally, their reliance on a single product and lack of diversity in their operations poses potential risks for the company's future success.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares